2004 Vol.22, N°5 - Suppl.35 - Table of contents

Benefit/risk of new drugs for rheumatoid arthritis

Guest Editors: A. Kavanaugh, R.F. van Vollenhoven, T. Pincus

Introduction

CER2363
2004,22,5,Suppl.35
Pg. 0001

Free to view

Introduction
A. Kavanaugh, R.F. van Vollenhoven, T. Pincus

Full Papers

CER2364
2004,22,5,Suppl.35
Pg. 0002-0011

Free to view

"Benefit/risk of therapies for rheumatoid arthritis: Underestimation of the ""side effects"" or risks of ra leads to underestimation of the benefit/risk of therapies"
T. Pincus, A. Kavanaugh, T. Sokka

CER2365
2004,22,5,Suppl.35
Pg. 0012-0017

Free to view

Undifferentiated arthritis - Disease course assessed in several inception cohorts
K.N. Verpoort, H. van Dongen, C.F. Allaart, R.E.M. Toes, F.C. Breedveld, T.W.J. Huizinga

CER2366
2004,22,5,Suppl.35
Pg. 0018-0025

Free to view

New approaches to imaging early inflammatory arthritis
A.K. Brown, R.J. Wakefield, P.G. Conaghan, Z. Karim, P.J. O’Connor, P. Emery

CER2367
2004,22,5,Suppl.35
Pg. 0026-0033

Free to view

Quantitative documentation of benefit/risk of new therapies for rheumatoid arthritis: Patient questionnaires as an optimal measure in standard care
T. Pincus, T. Sokka, A. Kavanaugh

CER2368
2004,22,5,Suppl.35
Pg. 0034-0038

Free to view

Internet-based monitoring of patients with rheumatoid arthritis
S.J. Lee, L. Lenert, A. Kavanaugh

CER2369
2004,22,5,Suppl.35
Pg. 0039-0043

Free to view

Mandatory pharmacosurveillance – A Canadian model for access to therapy and research
S.G. Barr, L. Martin, C. Chung, W.P. Maksymowych

CER2370
2004,22,5,Suppl.35
Pg. 0044-0049

Free to view

Healing of erosive changes in rheumatoid arthritis
R. Rau, G. Herborn, S. Wassenberg

CER2371
2004,22,5,Suppl.35
Pg. 0050-0056

Free to view

Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for near remission of DAS or single measures
T. Pincus, T. Sokka, A. Kavanaugh

CER2372
2004,22,5,Suppl.35
Pg. 0057-0064

Free to view

Longer term benefits of treating rheumatoid arthritis: Assessment of radiographic damage and physical function in clinical trials
V. Strand

CER2373
2004,22,5,Suppl.35
Pg. 0065-0070

Free to view

Cost-effectiveness of anti-tumor necrosis factor agents
J.B. Wong

CER2374
2004,22,5,Suppl.35
Pg. 0071-0076

Free to view

Benefit/risk of combination therapies
D. Zerkak, M. Dougados

CER2375
2004,22,5,Suppl.35
Pg. 0077-0082

Free to view

Glucocorticoid use in rheumatoid arthritis: Benefits, mechanisms, and risks
H.B. Townsend, K.G. Saag

CER2376
2004,22,5,Suppl.35
Pg. 0083-0094

Free to view

Benefit and risk of methotrexate treatment in rheumatoid arthritis
R. Rau, G. Herborn

CER2377
2004,22,5,Suppl.35
Pg. 0095-0100

Free to view

Benefit/risk of leflunomide in rheumatoid arthritis
J.M. Kremer, G.W. Cannon

CER2378
2004,22,5,Suppl.35
Pg. 0101-0107

Free to view

Benefit/risk of cyclosporine in rheumatoid arthritis
E. Gremese, G.F. Ferraccioli

CER2379
2004,22,5,Suppl.35
Pg. 0108-0114

Free to view

Overview of benefit/risk of biological agents
A.K. Imperato, C.O. Bingham III, S.B. Abramson

CER2380
2004,22,5,Suppl.35
Pg. 0115-0121

Free to view

Switching between biological agents
R.F. van Vollenhoven

CER2381
2004,22,5,Suppl.35
Pg. 0122-0125

Free to view

Benefits and risks of biological agents: Lymphomas
R.F. van Vollenhoven

CER2382
2004,22,5,Suppl.35
Pg. 0126-0133

Free to view

Tuberculosis and opportunistic infections: Relevance to biologic agents
J. Bieber, A. Kavanaugh

CER2383
2004,22,5,Suppl.35
Pg. 0134-0140

Free to view

Demyelination and inhibition of tumor necrosis factor (TNF)
M.D. Magnano, W.H. Robinson, M.C. Genovese

CER2384
2004,22,5,Suppl.35
Pg. 0141-0147

Free to view

Unusual toxicities with TNF inhibition: Heart failure and drug-induced lupus
J.J. Cush

CER2385
2004,22,5,Suppl.35
Pg. 0148-0150

Free to view

Safety issues related to emerging therapies for rheumatoid arthritis
E.C. Keystone